|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: EIF3H |
Gene summary for EIF3H |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | EIF3H | Gene ID | 8667 |
| Gene name | eukaryotic translation initiation factor 3 subunit H | |
| Gene Alias | EIF3S3 | |
| Cytomap | 8q23.3-q24.11 | |
| Gene Type | protein-coding | GO ID | GO:0001732 | UniProtAcc | O15372 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8667 | EIF3H | GSM4909281 | Human | Breast | IDC | 8.81e-26 | 4.78e-01 | 0.21 |
| 8667 | EIF3H | GSM4909282 | Human | Breast | IDC | 1.96e-03 | 1.85e-01 | -0.0288 |
| 8667 | EIF3H | GSM4909285 | Human | Breast | IDC | 1.18e-36 | 5.55e-01 | 0.21 |
| 8667 | EIF3H | GSM4909286 | Human | Breast | IDC | 1.35e-29 | 5.27e-01 | 0.1081 |
| 8667 | EIF3H | GSM4909288 | Human | Breast | IDC | 2.51e-03 | -1.30e-01 | 0.0988 |
| 8667 | EIF3H | GSM4909290 | Human | Breast | IDC | 4.64e-65 | 7.72e-01 | 0.2096 |
| 8667 | EIF3H | GSM4909291 | Human | Breast | IDC | 5.82e-16 | 3.93e-01 | 0.1753 |
| 8667 | EIF3H | GSM4909294 | Human | Breast | IDC | 1.33e-13 | 1.72e-02 | 0.2022 |
| 8667 | EIF3H | GSM4909296 | Human | Breast | IDC | 1.80e-34 | 3.66e-01 | 0.1524 |
| 8667 | EIF3H | GSM4909297 | Human | Breast | IDC | 2.48e-32 | -2.23e-01 | 0.1517 |
| 8667 | EIF3H | GSM4909301 | Human | Breast | IDC | 2.25e-22 | -5.47e-01 | 0.1577 |
| 8667 | EIF3H | GSM4909305 | Human | Breast | IDC | 2.13e-09 | 3.80e-01 | 0.0436 |
| 8667 | EIF3H | GSM4909306 | Human | Breast | IDC | 6.40e-09 | 3.12e-01 | 0.1564 |
| 8667 | EIF3H | GSM4909307 | Human | Breast | IDC | 5.68e-33 | 5.15e-01 | 0.1569 |
| 8667 | EIF3H | GSM4909308 | Human | Breast | IDC | 1.07e-104 | 8.68e-01 | 0.158 |
| 8667 | EIF3H | GSM4909309 | Human | Breast | IDC | 3.16e-07 | -9.62e-02 | 0.0483 |
| 8667 | EIF3H | GSM4909311 | Human | Breast | IDC | 2.50e-59 | 7.91e-02 | 0.1534 |
| 8667 | EIF3H | GSM4909312 | Human | Breast | IDC | 1.70e-107 | 9.46e-01 | 0.1552 |
| 8667 | EIF3H | GSM4909313 | Human | Breast | IDC | 2.72e-04 | -1.84e-02 | 0.0391 |
| 8667 | EIF3H | GSM4909315 | Human | Breast | IDC | 8.24e-32 | 4.37e-01 | 0.21 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:200005820 | Oral cavity | OSCC | regulation of ubiquitin-dependent protein catabolic process | 118/7305 | 164/18723 | 9.37e-18 | 9.27e-16 | 118 |
| GO:007182620 | Oral cavity | OSCC | ribonucleoprotein complex subunit organization | 152/7305 | 227/18723 | 1.05e-17 | 1.01e-15 | 152 |
| GO:003243420 | Oral cavity | OSCC | regulation of proteasomal ubiquitin-dependent protein catabolic process | 100/7305 | 134/18723 | 4.72e-17 | 4.04e-15 | 100 |
| GO:002261820 | Oral cavity | OSCC | ribonucleoprotein complex assembly | 146/7305 | 220/18723 | 1.53e-16 | 1.23e-14 | 146 |
| GO:00064469 | Oral cavity | OSCC | regulation of translational initiation | 64/7305 | 79/18723 | 2.32e-14 | 1.30e-12 | 64 |
| GO:000989519 | Oral cavity | OSCC | negative regulation of catabolic process | 180/7305 | 320/18723 | 2.44e-10 | 6.86e-09 | 180 |
| GO:000218318 | Oral cavity | OSCC | cytoplasmic translational initiation | 31/7305 | 34/18723 | 2.97e-10 | 8.14e-09 | 31 |
| GO:003133020 | Oral cavity | OSCC | negative regulation of cellular catabolic process | 152/7305 | 262/18723 | 3.04e-10 | 8.28e-09 | 152 |
| GO:004217719 | Oral cavity | OSCC | negative regulation of protein catabolic process | 77/7305 | 121/18723 | 3.49e-08 | 6.64e-07 | 77 |
| GO:004586120 | Oral cavity | OSCC | negative regulation of proteolysis | 181/7305 | 351/18723 | 1.01e-06 | 1.37e-05 | 181 |
| GO:200005919 | Oral cavity | OSCC | negative regulation of ubiquitin-dependent protein catabolic process | 35/7305 | 48/18723 | 1.93e-06 | 2.47e-05 | 35 |
| GO:190336317 | Oral cavity | OSCC | negative regulation of cellular protein catabolic process | 49/7305 | 75/18723 | 3.49e-06 | 4.15e-05 | 49 |
| GO:00324359 | Oral cavity | OSCC | negative regulation of proteasomal ubiquitin-dependent protein catabolic process | 26/7305 | 35/18723 | 2.40e-05 | 2.26e-04 | 26 |
| GO:190305117 | Oral cavity | OSCC | negative regulation of proteolysis involved in cellular protein catabolic process | 41/7305 | 64/18723 | 4.31e-05 | 3.71e-04 | 41 |
| GO:000173218 | Oral cavity | OSCC | formation of cytoplasmic translation initiation complex | 14/7305 | 16/18723 | 9.15e-05 | 6.93e-04 | 14 |
| GO:19017998 | Oral cavity | OSCC | negative regulation of proteasomal protein catabolic process | 31/7305 | 49/18723 | 5.04e-04 | 2.95e-03 | 31 |
| GO:0002181110 | Oral cavity | LP | cytoplasmic translation | 124/4623 | 148/18723 | 5.09e-52 | 3.19e-48 | 124 |
| GO:0022613110 | Oral cavity | LP | ribonucleoprotein complex biogenesis | 259/4623 | 463/18723 | 7.20e-48 | 2.25e-44 | 259 |
| GO:0071826110 | Oral cavity | LP | ribonucleoprotein complex subunit organization | 130/4623 | 227/18723 | 7.54e-26 | 3.63e-23 | 130 |
| GO:0010498110 | Oral cavity | LP | proteasomal protein catabolic process | 224/4623 | 490/18723 | 9.57e-25 | 4.00e-22 | 224 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa051629 | Esophagus | ESCC | Measles | 90/4205 | 139/8465 | 2.16e-04 | 7.87e-04 | 4.03e-04 | 90 |
| hsa0516213 | Esophagus | ESCC | Measles | 90/4205 | 139/8465 | 2.16e-04 | 7.87e-04 | 4.03e-04 | 90 |
| hsa051628 | Oral cavity | OSCC | Measles | 90/3704 | 139/8465 | 4.10e-07 | 2.50e-06 | 1.27e-06 | 90 |
| hsa0516212 | Oral cavity | OSCC | Measles | 90/3704 | 139/8465 | 4.10e-07 | 2.50e-06 | 1.27e-06 | 90 |
| hsa0516221 | Oral cavity | LP | Measles | 59/2418 | 139/8465 | 2.90e-04 | 1.60e-03 | 1.03e-03 | 59 |
| hsa0516231 | Oral cavity | LP | Measles | 59/2418 | 139/8465 | 2.90e-04 | 1.60e-03 | 1.03e-03 | 59 |
| hsa0516241 | Oral cavity | EOLP | Measles | 42/1218 | 139/8465 | 1.11e-06 | 9.96e-06 | 5.87e-06 | 42 |
| hsa051625 | Oral cavity | EOLP | Measles | 42/1218 | 139/8465 | 1.11e-06 | 9.96e-06 | 5.87e-06 | 42 |
| hsa051626 | Oral cavity | NEOLP | Measles | 35/1112 | 139/8465 | 8.30e-05 | 6.14e-04 | 3.86e-04 | 35 |
| hsa051627 | Oral cavity | NEOLP | Measles | 35/1112 | 139/8465 | 8.30e-05 | 6.14e-04 | 3.86e-04 | 35 |
| hsa051624 | Prostate | BPH | Measles | 42/1718 | 139/8465 | 3.35e-03 | 1.23e-02 | 7.61e-03 | 42 |
| hsa0516211 | Prostate | BPH | Measles | 42/1718 | 139/8465 | 3.35e-03 | 1.23e-02 | 7.61e-03 | 42 |
| hsa051622 | Prostate | Tumor | Measles | 44/1791 | 139/8465 | 2.33e-03 | 8.85e-03 | 5.49e-03 | 44 |
| hsa051623 | Prostate | Tumor | Measles | 44/1791 | 139/8465 | 2.33e-03 | 8.85e-03 | 5.49e-03 | 44 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| EIF3H | SNV | Missense_Mutation | rs765673805 | c.947N>T | p.Ser316Leu | p.S316L | O15372 | protein_coding | deleterious(0.02) | benign(0.062) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| EIF3H | SNV | Missense_Mutation | c.685N>A | p.Glu229Lys | p.E229K | O15372 | protein_coding | tolerated(0.27) | benign(0.095) | TCGA-EA-A50E-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | |
| EIF3H | SNV | Missense_Mutation | novel | c.150N>G | p.Ile50Met | p.I50M | O15372 | protein_coding | deleterious(0) | probably_damaging(0.981) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
| EIF3H | SNV | Missense_Mutation | c.101N>T | p.Ser34Leu | p.S34L | O15372 | protein_coding | tolerated(0.05) | benign(0.034) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| EIF3H | SNV | Missense_Mutation | rs776462055 | c.550C>A | p.Pro184Thr | p.P184T | O15372 | protein_coding | tolerated(0.22) | benign(0.039) | TCGA-AA-3845-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| EIF3H | SNV | Missense_Mutation | novel | c.766N>A | p.Asp256Asn | p.D256N | O15372 | protein_coding | deleterious(0) | benign(0.042) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| EIF3H | SNV | Missense_Mutation | novel | c.7N>C | p.Ser3Pro | p.S3P | O15372 | protein_coding | deleterious_low_confidence(0.01) | benign(0.027) | TCGA-AA-A01R-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5-fluorouracil | PD |
| EIF3H | SNV | Missense_Mutation | c.85N>T | p.Gly29Cys | p.G29C | O15372 | protein_coding | deleterious(0.02) | probably_damaging(0.979) | TCGA-D5-6928-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| EIF3H | SNV | Missense_Mutation | c.314N>A | p.Arg105Gln | p.R105Q | O15372 | protein_coding | deleterious(0.03) | benign(0.266) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| EIF3H | SNV | Missense_Mutation | rs367787019 | c.340N>T | p.His114Tyr | p.H114Y | O15372 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AG-A023-01 | Colorectum | rectum adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |